Lily Wong

Dynamic Senior Scientist with extensive experience in analytical development at Pfizer, specializing in cell-based assays and method validation. Proven track record in enhancing drug product characterization and regulatory compliance. Adept at data analysis and leading cross-functional teams to achieve project milestones, driving innovation in CAR-T therapies.

• DePrimo, S.E., Wong, L.M., Khatry, D.B., Nicholas, S.L., Manning, W.C., Smolich, B.D., O’Farrell, A-M., Cherrington, J.M., Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification., BMC Cancer, 2003, 3, 3, http://www.biomedcentral.com/1471-2407/3/3
• O’Farrell, A-M., Abrams, T.J., Yuen, H.A., Ngai, T.J., Louie, S.G., Yee, K.W., Wong, L.M., Hong, W., Lee, L.B., Town, A., Smolich, B.D., Manning, W.C., Murray, L.J., Heinrich, M.C., Cherrington, J.M., SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo., Blood, 2003, 101, 9, 3597-3605, http://www.bloodjournal.org/content/101/9/3597

• Ahene, A., Cao, L., Chen, J., Espinoza, Y., Wong, L., Shimizu, R., Wong, D., Development and Validation of Immunoassays for the Detection and Confirmation of Anti-drug Antibodies of Two Co-formulated Combination Anti-botulism Drug Candidates in Rats., 2014 AAPS National Biotechnology Conference, San Diego, CA, 05/14
• Chen, J., Wong, L., Cao, L., Gasper, C., Ma, J., Ahene, A., Toxicokinetics and Immunogenicity of Gevokizumab in Pre- and Postnatal Development in Rats., 2013 AAPS National Biotechnology Conference, San Diego, CA, 05/13